Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00462072 · ClinicalTrials.gov registry record · Phase 4

Centocor Microarray Study of Patients

A Phase 4 study of Rheumatoid Arthritis and Psoriasis, sponsored by University of Rochester.

Completed
Registry status
Phase 4
Development phase
31
Enrollment target
1
Study location

NCT00462072 is a Phase 4 study of Rheumatoid Arthritis and Psoriasis that has completed, run by University of Rochester. The registered enrollment target is 31 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00462072, a Phase 4 study of Rheumatoid Arthritis and Psoriasis, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
Phase 4
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

Specific Aim 1. To determine the transcriptome of peripheral blood mononuclear cells isolated monocytes and target tissues in IMIDs. Specific Aim 2. To analyze the change in gene expression profiles in patients with Crohn's disease, psoriatic and rheumatoid arthritis before and after infliximab therapy.

Interventions

  • DRUG Infliximab

Study Locations (1)

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2007-03
Est. Completion 2010-08
Phase Phase 4

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT00462072

The ClinicalTrials.gov registry entry for NCT00462072 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Infliximab is the first listed.

NCT00462072 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00462072 about?

NCT00462072 is a clinical study titled "Centocor Microarray Study of Patients". Specific Aim 1. To determine the transcriptome of peripheral blood mononuclear cells isolated monocytes and target tissues in IMIDs. Specific Aim 2. To analyze the change in gene expression profiles in patients with Crohn's disease, psoriatic and rheumatoid arthritis before and after infliximab the...

What is the current status of trial NCT00462072?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2007-03. Estimated completion is 2010-08.

What conditions does trial NCT00462072 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Psoriatic Arthritis.

What interventions are being tested in trial NCT00462072?

The interventions under investigation include: Infliximab (DRUG).

Who is sponsoring clinical trial NCT00462072?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00462072 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.